Key result
Greater LGE extent is linked to ~24% higher MACE risk in dilated cardiomyopathy.
Why the study?
This study aimed to investigate the prognostic value of late gadolinium enhancement (LGE) extent for MACE in dilated cardiomyopathy (DCM) patients and characterize the dynamic pattern of its risk effect over time.
Does late gadolinium enhancement (LGE) extent on cardiac magnetic resonance predict major adverse cardiovascular events (MACE) with a time-varying risk pattern in patients with dilated cardiomyopathy?
Cohort (n=173)
Does late gadolinium enhancement (LGE) extent on cardiac magnetic resonance predict major adverse cardiovascular events (MACE) with a time-varying risk pattern in patients with dilated cardiomyopathy?
In patients with dilated cardiomyopathy, LV LGE extent and LVEDVi independently predict MACE, with the risk effect of LGE extent demonstrating time-dependent attenuation over follow-up.
LGE extent may aid early DCM risk stratification; leaves open whether time-varying attenuation warrants prospective intervention trials.
Objectives To investigate the prognostic value of late gadolinium enhancement (LGE) extent for major adverse cardiovascular events (MACE) in dilated cardiomyopathy (DCM) patients and characterize the dynamic pattern of its risk effect over time. Methods We retrospectively enrolled patients who underwent Cardiac Magnetic Resonance (CMR) between 2020 and 2024, with MACE (cardiac death, heart failure re‐hospitalization, or sustained ventricular arrhythmia) as the endpoint. Patients were stratified by MACE occurrence. Schoenfeld residual testing showed borderline deviation of the proportional hazards (PH) assumption for LGE extent (LV mass percentage). Thus, a time‐dependent Cox model (Extended Cox PHs Model) with an LGE extent × follow‐up time interaction term was built to assess dynamic hazard ratio changes, and independent MACE risk factors were identified. Results Among 173 DCM patients (age 47 ± 15 years, 105 males), 46 (26.6%) experienced MACE after a mean follow‐up of 27 ± 16 months. The time‐dependent Cox model identified LGE extent (baseline HR: 1.243, 95% CI: 1.162–1.329, p < 0.001), the LGE extent × time interaction (HR: 0.993, 95% CI: 0.989–0.997, p = 0.001), and LV end‐diastolic volume index (LVEDVi; HR = 1.008, 95% CI: 1.003–1.014, p = 0.001) as independent MACE predictors. Notably, the risk effect of LGE extent demonstrated time‐dependent attenuation. Conclusion LV LGE extent and LVEDVi independently predict MACE in DCM patients. The early prognostic value of LGE extent suggests a critical time window for early fibrosis intervention.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a cohort in Dilated cardiomyopathy (DCM) (n=173). Late gadolinium enhancement (LGE) extent (LV mass percentage) was evaluated on Major adverse cardiovascular events (MACE: cardiac death, heart failure re-hospitalization, or sustained ventricular arrhythmia) (HR 1.243, 95% CI 1.162-1.329, p=<0.001). Late gadolinium enhancement extent independently predicted MACE in dilated cardiomyopathy (baseline HR 1.243, 95% CI 1.162-1.329, p<0.001) with time-dependent attenuation (interaction HR 0.993).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: